Zermat Skin Spf 50 Broad Spectrum

Avobenzone, Homosalate, Octinoxate, Octisalate


Zermat Internacional S.a. De C.v.
Human Otc Drug
NDC 15828-737
Zermat Skin Spf 50 Broad Spectrum also known as Avobenzone, Homosalate, Octinoxate, Octisalate is a human otc drug labeled by 'Zermat Internacional S.a. De C.v.'. National Drug Code (NDC) number for Zermat Skin Spf 50 Broad Spectrum is 15828-737. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Zermat Skin Spf 50 Broad Spectrum drug includes Avobenzone - 30 mg/g Homosalate - 100 mg/g Octinoxate - 75 mg/g Octisalate - 50 mg/g . The currest status of Zermat Skin Spf 50 Broad Spectrum drug is Active.

Drug Information:

Drug NDC: 15828-737
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Zermat Skin Spf 50 Broad Spectrum
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Avobenzone, Homosalate, Octinoxate, Octisalate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Zermat Internacional S.a. De C.v.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:AVOBENZONE - 30 mg/g
HOMOSALATE - 100 mg/g
OCTINOXATE - 75 mg/g
OCTISALATE - 50 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 15 Apr, 2016
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Zermat Internacional S.A. de C.V.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0401408010705
UPC stands for Universal Product Code.
UNII:G63QQF2NOX
V06SV4M95S
4Y5P7MUD51
4X49Y0596W
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
15828-737-011 TUBE in 1 BOX (15828-737-01) / 48 g in 1 TUBE15 Apr, 2016N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Sunscreen

Product Elements:

Zermat skin spf 50 broad spectrum avobenzone, homosalate, octinoxate, octisalate aloe vera leaf water ascorbic acid shea butter c13-14 isoparaffin green tea leaf cetostearyl alcohol cetearyl olivate cocamidopropyl betaine cucumber cyclomethicone 4 cyclomethicone 5 ethylhexylglycerin glycerin glyceryl monostearate glyceryl stearate se sunflower oil isopropyl myristate laureth-7 mangifera indica seed butter peg-100 stearate phenoxyethanol polysorbate 20 punica granatum root bark sorbitan olivate .alpha.-tocopherol acetate avobenzone avobenzone homosalate homosalate octinoxate octinoxate octisalate octisalate

Indications and Usage:

Uses: helps prevent sunburn, if used as directed with other sun protection measure (see directions), decreases the risk of skin cancer and early skin aging caused by the sun.

Warnings:

Warnings: for external use only. do not use on damaged or broken skin. when using this product keep out of eyes. rinse with water to remove. stop use and consult physician if irritation or rash develops. keep out of reach of children. if product is swallowed, get medical attention or contact poison control center immediately.

Do Not Use:

Warnings: for external use only. do not use on damaged or broken skin. when using this product keep out of eyes. rinse with water to remove. stop use and consult physician if irritation or rash develops. keep out of reach of children. if product is swallowed, get medical attention or contact poison control center immediately.

When Using:

When using this product keep out of eyes. rinse with water to remove.

Dosage and Administration:

Directions: apply liberally 15-minutes before sun exposure. reapply: at least, every two-hours. immediately after swimming, sweating or towel drying. sun protection measures: spending time in the sun increases your risk of skin cancer and early skin aging. to decrease this risk, regularly use sunscreen with broad spectrum protection and an spf rating of 15 or higher, along with other sun protection measures including: limit time in the sun, especially between 10am and 2pm. wear long sleeve shirts, pants, hats and sunglasses. for children under 6 months, consult a physician.

Stop Use:

Stop use and consult physician if irritation or rash develops.

Package Label Principal Display Panel:

Package labeling: label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.